Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies

被引：0
|
作者：
Wainberg, Zev A.
Fuchs, Charles S.
Tabernero, Josep
Shitara, Kohei
Muro, Kei
Van Cutsem, Eric
Bang, Yung-Jue
Chung, Hyun Cheol
Yamaguchi, Kensei
Varga, Eniko
Chen, Jen-Shi
Hochhauser, Daniel
Thuss-Patience, Peter C.
Al-Batran, Salah-Eddin
Garrido, Marcelo
Kher, Uma
Shih, Chie-Schin
Shah, Sukrut
Bhagia, Pooja
Chao, Joseph
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Vall dHebron Inst Oncol, Barcelona, Spain
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[7] Univ Hosp, Leuven, Belgium
[8] Katholieke Univ Leuven, Leuven, Belgium
[9] Seoul Natl Univ Hosp, Seoul, South Korea
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] JFCR, Canc Inst Hosp, Tokyo, Japan
[12] Debreceni Egyet Klin Kozpont, Debrecen, Hungary
[13] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan
[14] UCL Hosp NHS Fdn Trust, London, England
[15] Charite Campus Virchow Klinikum, Berlin, Germany
[16] Inst Klin Onkol, Frankfurt, Germany
[17] Pontificia Univ Catolica Chile, Santiago, Chile
[18] Merck & Co Inc, Kenilworth, NJ USA
[19] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
427
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro plus chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
    Wyrwicz, L. S.
    Lee, K-W.
    Van Cutsem, E.
    Bang, Y-J.
    Fuchs, C. S.
    Kudaba, I.
    Garrido, M.
    Chung, H. C.
    Lee, J.
    Castro, H. R.
    Chao, J.
    Wainberg, Z. A.
    Cao, Z. A.
    Aurora-Garg, D.
    Kobie, J.
    Cristescu, R.
    Bhagia, P.
    Shah, S.
    Tabernero, J.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S907 - S908
  • [32] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [33] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    Herbst, Roy S.
    Baas, Paul
    Kim, Dong-Wan
    Felip, Enriqueta
    Perez-Gracia, Jose L.
    Han, Ji-Youn
    Molina, Julian
    Kim, Joo-Hang
    Arvis, Catherine Dubos
    Ahn, Myung-Ju
    Majem, Margarita
    Fidler, Mary J.
    de Castro, Gilberto, Jr.
    Garrido, Marcelo
    Lubiniecki, Gregory M.
    Shentu, Yue
    Im, Ellie
    Dolled-Filhart, Marisa
    Garon, Edward B.
    LANCET, 2016, 387 (10027): : 1540 - 1550
  • [34] Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
    Cho, Byoung Chul
    Lopes, Gilberto
    Kowalski, Dariusz M.
    Kasahara, Kazuo
    Wu, Yi-Long
    Castro, Gilberto
    Turna, Hande Z.
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Loboda, Andrey
    Lunceford, Jared
    Kobie, Julie
    Ayers, Mark
    Pietanza, M. Catherine
    Piperdi, Bilal
    Mok, Tony S.
    CANCER RESEARCH, 2020, 80 (16)
  • [35] Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
    Brahmer, Julie R.
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Zhang, Jin
    Lubiniecki, Gregory M.
    Deitz, Anne C.
    Rangwala, Reshma
    Reck, Martin
    LANCET ONCOLOGY, 2017, 18 (12): : 1600 - 1609
  • [36] KEYNOTE-042: PHASE 3 STUDY OF PEMBROLIZUMAB (MK-3475) VERSUS PLATINUM DOUBLET CHEMOTHERAPY AS FIRST-LINE THERAPY FOR PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto
    Watson, Patricia A.
    Zhang, Jin
    Rangwala, Reshma
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S192 - S192
  • [37] Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
    Morales-Barrera, Rafael
    Powles, Thomas
    Ozguroglu, Mustafa
    Csoszi, Tibor
    Loriot, Yohann
    Flechon, Aude
    Matsubara, Nobuaki
    Rodriguez-Vida, Alejo
    Geczi, Lajos
    Cheng, Susanna Y.
    Fradet, Yves
    Oudard, Stephane
    Gunduz, Seyda
    Ma, Junshui
    Rajasagi, Mohini
    Vajdi, Amir
    Cristescu, Razvan
    Imai, Kentaro
    Moreno, Blanca Homet
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).
    Mok, Tony
    Wu, Yi-Long
    Watson, Patricia A.
    Zhang, Jin
    Rangwala, Reshma A.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumi
    Tamura, Kenji
    Armstrong, Anne
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Card, Deborah
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populations
    Rha, Sun Young
    Wyrwicz, Lucjan
    Weber, Patricio Eduardo Yanez
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve Aine
    Cil, Timucin
    Cruz, Felipe Melo
    Qin, Shukui
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345